These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

636 related items for PubMed ID: 10918610

  • 1. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R.
    Oncogene; 2000 Jul 20; 19(31):3521-8. PubMed ID: 10918610
    [Abstract] [Full Text] [Related]

  • 2. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
    Krystal GW, Honsawek S, Litz J, Buchdunger E.
    Clin Cancer Res; 2000 Aug 20; 6(8):3319-26. PubMed ID: 10955819
    [Abstract] [Full Text] [Related]

  • 3. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R.
    Cancer Res; 2002 Nov 01; 62(21):6304-11. PubMed ID: 12414661
    [Abstract] [Full Text] [Related]

  • 4. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
    Krystal GW, Honsawek S, Kiewlich D, Liang C, Vasile S, Sun L, McMahon G, Lipson KE.
    Cancer Res; 2001 May 01; 61(9):3660-8. PubMed ID: 11325836
    [Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL.
    Clin Cancer Res; 2004 May 15; 10(10):3528-34. PubMed ID: 15161712
    [Abstract] [Full Text] [Related]

  • 6. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
    Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R.
    Cancer Res; 2003 Oct 01; 63(19):6272-81. PubMed ID: 14559814
    [Abstract] [Full Text] [Related]

  • 7. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R.
    Clin Cancer Res; 2002 Feb 01; 8(2):620-7. PubMed ID: 11839685
    [Abstract] [Full Text] [Related]

  • 8. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.
    Krystal GW, Hines SJ, Organ CP.
    Cancer Res; 1996 Jan 15; 56(2):370-6. PubMed ID: 8542594
    [Abstract] [Full Text] [Related]

  • 9. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
    Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB.
    J Pharmacol Exp Ther; 2000 Oct 15; 295(1):139-45. PubMed ID: 10991971
    [Abstract] [Full Text] [Related]

  • 10. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
    Yokoyama T, Miyazawa K, Yoshida T, Ohyashiki K.
    Int J Oncol; 2005 Jan 15; 26(1):33-40. PubMed ID: 15586222
    [Abstract] [Full Text] [Related]

  • 11. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
    Krystal GW, DeBerry CS, Linnekin D, Litz J.
    Cancer Res; 1998 Oct 15; 58(20):4660-6. PubMed ID: 9788619
    [Abstract] [Full Text] [Related]

  • 12. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, André T, Mareel M, Mester J, Gespach C.
    Cancer Res; 2002 Sep 01; 62(17):4879-83. PubMed ID: 12208734
    [Abstract] [Full Text] [Related]

  • 13. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
    Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K.
    Oncol Rep; 2004 Nov 01; 12(5):1053-7. PubMed ID: 15492792
    [Abstract] [Full Text] [Related]

  • 14. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
    Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S, Serra M, Astolfi A, Nicoletti G, Lollini PL, Bertoni F, Nanni P, Picci P.
    J Clin Oncol; 2003 May 15; 21(10):1952-60. PubMed ID: 12743148
    [Abstract] [Full Text] [Related]

  • 15. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA, Laug WE, Sausville EA, Avramis VI.
    Cancer Chemother Pharmacol; 2003 Oct 15; 52(4):307-18. PubMed ID: 12827297
    [Abstract] [Full Text] [Related]

  • 16. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines.
    Ali MA, Rosati R, Pettit GR, Kalemkerian GP.
    Anticancer Res; 1998 Oct 15; 18(2A):1021-6. PubMed ID: 9615758
    [Abstract] [Full Text] [Related]

  • 17. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.
    Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW.
    Lung Cancer; 2004 Dec 15; 46(3):283-91. PubMed ID: 15541812
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT.
    Cancer; 2005 May 15; 103(10):2128-31. PubMed ID: 15812822
    [Abstract] [Full Text] [Related]

  • 19. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
    Suyama H, Igishi T, Ueda Y, Shigeoka Y, Kodani M, Morita M, Takeda K, Sumikawa T, Nakazaki H, Matsunami K, Matsumoto S, Shimizu E.
    Oncol Rep; 2010 Jan 15; 23(1):217-22. PubMed ID: 19956885
    [Abstract] [Full Text] [Related]

  • 20. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Aug 15; 116(8):1409-16. PubMed ID: 16885745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.